AXA Investment Managers’s Denali Therapeutics DNLI Stock Holding History

AXA Investment Managers’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$4.28M	Buy	+294,732	New	+$4.24M	0.01%	602

Other funds holding DNLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AXA Investment Managers's DNLI Position: Q3 2025 in Review

AXA Investment Managers opened a new position in Denali Therapeutics (DNLI) in Q3 2025: 294,732 shares worth $4.28M. The stake represents 0.01% of the portfolio and ranks #602 among its holdings.

240 funds tracked by Wall St. Rank hold DNLI as of Q3 2025.

AXA Investment Managers held 294,732 shares of Denali Therapeutics worth $4.28M as of Q3 2025.
Denali Therapeutics was a new AXA Investment Managers position in Q3 2025.
Denali Therapeutics made up 0.01% of AXA Investment Managers's portfolio in Q3 2025, its #602 holding.
240 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2025.

Based on AXA Investment Managers's 13F filing for Q3 2025, filed 14 Nov 2025.